Literature DB >> 19811880

Clinical factors associated with seroma volume reduction in breast-Conserving Therapy for early-stage breast cancer: a multi-institutional analysis.

Tzu-I J Yang1, Paula H M Elkhuizen, Danny Minkema, Wilma Heemsbergen, Anke M van Mourik, Jorien Cassee, Coen Hurkmans, Corine van Vliet-Vroegindeweij.   

Abstract

PURPOSE: To correlate clinical factors with seroma volume and reduction; and to determine whether cone-beam CT (CBCT) could be used clinically to monitor seroma reduction. PATIENTS AND METHODS: This investigation included 102 women from five institutions with stage T1-2 breast cancer treated with breast-conserving therapy. Two CT scans were acquired: the planning CT (CT1) and a second CT (CT2) during radiotherapy (RT). Seroma was contoured on all scans, and correlations between seroma characteristics and clinical factors were investigated by univariate and multivariate analyses. In a substudy, 10 of the 102 patients received multiple CBCT scans during RT. Seroma were contoured by two observers in the substudy. Fifteen time points at which CT and CBCT were performed within 2 days were identified. The levels of correlation in seroma contours between CBCT and CT and between the two observers were examined.
RESULTS: The mean relative seroma reduction from CT1 to CT2 was 54% (p < 0.001). A significant inverse relationship was found between relative seroma reduction per week and number of RT fractions given by univariate and multivariate analyses (p = 0.01, 0.03). The mean difference in contoured seroma volumes between CT and CBCT was 12% (3.3 cm(3)). When assessing the relative difference in seroma contours between Observer 1 and Observer 2, an interobserver difference of 12% was demonstrated. Neither discrepancy was clinically significant.
CONCLUSIONS: Radiotherapy seems to hinder seroma reduction. Volume discrepancies between CBCT and CT were minor, with low interobserver variation, indicating that CBCT might be useful in monitoring seroma reduction.

Entities:  

Mesh:

Year:  2009        PMID: 19811880     DOI: 10.1016/j.ijrobp.2009.03.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Set-up uncertainty during breast radiotherapy. Image-guided radiotherapy for patients with initial extensive variation.

Authors:  D S Yang; W S Yoon; S Y Chung; J A Lee; S Lee; Y J Park; C Y Kim; G S Son
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

2.  Magnetic Resonance Imaging for Breast Tumor Bed Delineation: Computed Tomography Comparison and Sequence Variation.

Authors:  Nicola Lowrey; Christine A Koch; Thomas Purdie; Anna Simeonov; Leigh Conroy; Kathy Han
Journal:  Adv Radiat Oncol       Date:  2021-05-26

3.  Seroma change during magnetic resonance imaging-guided partial breast irradiation and its clinical implications.

Authors:  Seung Hyuck Jeon; Kyung Hwan Shin; So-Yeon Park; Jung-In Kim; Jong Min Park; Jin Ho Kim; Eui Kyu Chie; Hong-Gyun Wu
Journal:  Radiat Oncol       Date:  2017-06-20       Impact factor: 3.481

4.  Breast-shape changes during radiation therapy after breast-conserving surgery.

Authors:  Tanja Alderliesten; Wilma D Heemsbergen; Anja Betgen; Rajko Topolnjak; Paula H M Elkhuizen; Corine van Vliet-Vroegindeweij; Peter Remeijer
Journal:  Phys Imaging Radiat Oncol       Date:  2018-05-31

5.  Detection of setup errors with a body-surface laser-scanning system for whole-breast irradiation after breast-conserving surgery.

Authors:  Ping Jiang; Ziyi Liu; Weijuan Jiang; Ang Qu; Haitao Sun; Junjie Wang
Journal:  J Appl Clin Med Phys       Date:  2022-03-16       Impact factor: 2.243

6.  Cone-beam computed tomography image guided therapy to evaluate lumpectomy cavity variation before and during breast radiotherapy.

Authors:  Minh Tam Truong; Ariel E Hirsch; Nataliya Kovalchuk; Muhammad M Qureshi; Antonio Damato; Bradley Schuller; Nectaria Vassilakis; Michael Stone; David Gierga; John Willins; Lisa A Kachnic
Journal:  J Appl Clin Med Phys       Date:  2013-03-04       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.